Valuation is a hot topic among life sciences professionals. There is no clear understanding on how to use the different valuation approaches and how to determine input parameters. Some do not value at all, arguing that it is not possible to get realistic and objective numbers out of it. Some claim it to be an art. In the following chapters we will provide the user with a concise val- tion manual, providing transparency and practical insight for all dealing with valuation in life sciences: project and portfolio managers, licensing executives, business developers, technology transfer managers, entrep- neurs, investors, and analysts. The purpose of the book is to explain how to apply discounted cash flow and real options valuation to life sciences p- jects, i.e. to license contracts, patents, and firms. We explain the fun- mentals and the pitfalls with case studies so that the reader is capable of performing the valuations on his own and repeat the theory in the exercises and case studies. The book is structured in five parts: In the first part, the introduction, we discuss the role of the players in the life sciences industry and their p- ticular interests. We describe why valuation is important to them, where they need it, and the current problems to it. The second part deals with the input parameters required for valuation in life sciences, i.e. success rates, costs, peak sales, and timelines.
"Sinopsis" puede pertenecer a otra edición de este libro.
This book is the first complete guide to valuation in life sciences for industry professionals, investors, and academics. Boris Bogdan and Ralph Villiger introduce the characteristics of drug and medical device development, explain how to translate these into the valuation, and provide valuable industry data. After guiding the reader through the theory of valuation, including DCF, decision trees, and real options, the authors demonstrate how to value projects, patents, licences, firms, and stocks on real-life examples, even treating complex licence and company structures. Special emphasis is put on the practicability of the proposed methods by including many hands-on examples, without compromising on realistic results.
The 3rd edition of the successful work includes new studies about success rates and about drug development in the biotech industry and their influence on valuation.
"Sobre este título" puede pertenecer a otra edición de este libro.
EUR 9,00 gastos de envío desde Alemania a España
Destinos, gastos y plazos de envíoEUR 4,72 gastos de envío desde Reino Unido a España
Destinos, gastos y plazos de envíoLibrería: BücherBirne, Kaufbeuren, Alemania
Hardcover. Condición: Fine. Buch in noch sehr gut erhaltenem Zustand. Der Einband ist unbeschädigt, unbestoßen und unberieben. Die Kanten und der Buchrücken können minimal bestoßen/berieben sein, ansonsten ist der Buchdeckel/Einband unbeschadet. Die Seiten sind sauber, knickfrei und unbeschädigt. Die Schnittkanten sind sauber, nicht nachgedunkelt. Keine Eintragungen, oder Markierungen. Ein schönes und sehr gut erhaltenes Exemplar, welches nur sehr geringfügige, hauptsächlich äußerliche Alters-/Gebrauchsspuren aufweisen kann. ---- Versandhinweise : Versand innerhalb von 24 Stunden. Lieferung erfolgt in der Regel innerhalb von 2-7 Werktagen. Kostenlose Rücknahme bei Nichtgefallen innerhalb von 14 Tagen. Rechnung mit MwSt-Ausweis. 4/3/027---. nein. Nº de ref. del artículo: 27819
Cantidad disponible: 1 disponibles
Librería: Ria Christie Collections, Uxbridge, Reino Unido
Condición: New. In English. Nº de ref. del artículo: ria9783642108198_new
Cantidad disponible: Más de 20 disponibles
Librería: moluna, Greven, Alemania
Gebunden. Condición: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. First complete guide to valuation in life sciences (pharma, biotech, medtech)Step-by-step explanation of how to practice valuation of projects and contractsWith relevant data and many real-life examples and exercisesValuation is a h. Nº de ref. del artículo: 5049358
Cantidad disponible: Más de 20 disponibles
Librería: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Alemania
Buch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Valuation is a hot topic among life sciences professionals. There is no clear understanding on how to use the different valuation approaches and how to determine input parameters. Some do not value at all, arguing that it is not possible to get realistic and objective numbers out of it. Some claim it to be an art. In the following chapters we will provide the user with a concise val- tion manual, providing transparency and practical insight for all dealing with valuation in life sciences: project and portfolio managers, licensing executives, business developers, technology transfer managers, entrep- neurs, investors, and analysts. The purpose of the book is to explain how to apply discounted cash flow and real options valuation to life sciences p- jects, i.e. to license contracts, patents, and firms. We explain the fun- mentals and the pitfalls with case studies so that the reader is capable of performing the valuations on his own and repeat the theory in the exercises and case studies. The book is structured in five parts: In the first part, the introduction, we discuss the role of the players in the life sciences industry and their p- ticular interests. We describe why valuation is important to them, where they need it, and the current problems to it. The second part deals with the input parameters required for valuation in life sciences, i.e. success rates, costs, peak sales, and timelines. 370 pp. Englisch. Nº de ref. del artículo: 9783642108198
Cantidad disponible: 2 disponibles
Librería: AHA-BUCH GmbH, Einbeck, Alemania
Buch. Condición: Neu. Druck auf Anfrage Neuware - Printed after ordering - Valuation is a hot topic among life sciences professionals. There is no clear understanding on how to use the different valuation approaches and how to determine input parameters. Some do not value at all, arguing that it is not possible to get realistic and objective numbers out of it. Some claim it to be an art. In the following chapters we will provide the user with a concise val- tion manual, providing transparency and practical insight for all dealing with valuation in life sciences: project and portfolio managers, licensing executives, business developers, technology transfer managers, entrep- neurs, investors, and analysts. The purpose of the book is to explain how to apply discounted cash flow and real options valuation to life sciences p- jects, i.e. to license contracts, patents, and firms. We explain the fun- mentals and the pitfalls with case studies so that the reader is capable of performing the valuations on his own and repeat the theory in the exercises and case studies. The book is structured in five parts: In the first part, the introduction, we discuss the role of the players in the life sciences industry and their p- ticular interests. We describe why valuation is important to them, where they need it, and the current problems to it. The second part deals with the input parameters required for valuation in life sciences, i.e. success rates, costs, peak sales, and timelines. Nº de ref. del artículo: 9783642108198
Cantidad disponible: 2 disponibles
Librería: GreatBookPricesUK, Woodford Green, Reino Unido
Condición: New. Nº de ref. del artículo: 9134668-n
Cantidad disponible: Más de 20 disponibles
Librería: GreatBookPrices, Columbia, MD, Estados Unidos de America
Condición: New. Nº de ref. del artículo: 9134668-n
Cantidad disponible: 5 disponibles
Librería: California Books, Miami, FL, Estados Unidos de America
Condición: New. Nº de ref. del artículo: I-9783642108198
Cantidad disponible: Más de 20 disponibles
Librería: Books Puddle, New York, NY, Estados Unidos de America
Condición: New. pp. 386 3rd Edition. Nº de ref. del artículo: 261375711
Cantidad disponible: 4 disponibles
Librería: Majestic Books, Hounslow, Reino Unido
Condición: New. Print on Demand pp. 386 Illus. Nº de ref. del artículo: 6504960
Cantidad disponible: 4 disponibles